Search

Your search keyword '"Minařík, Jiří"' showing total 132 results

Search Constraints

Start Over You searched for: Author "Minařík, Jiří" Remove constraint Author: "Minařík, Jiří"
132 results on '"Minařík, Jiří"'

Search Results

1. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

3. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

4. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

8. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

10. Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma

13. Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

14. Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

15. 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group

16. Retinal oxygen saturation in monoclonal gammopathies patients: A pilot study.

17. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

18. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data

22. Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

23. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

24. Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

25. P-159 Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence

26. P-075 Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience

29. Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model

33. P-177: Outcomes in risk-stratified patients with smoldering multiple myeloma: a retrospective analysis of real-world data from the Czech Registry of Monoclonal Gammopathies

35. OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis

39. Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients

41. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients

43. Vliv zatížení a tlaku huštění pneumatik traktoru na utužení půdy

44. Vyhodnocení ohroženosti pozemků vodní erozí na vybraném území

47. Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

49. Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

Catalog

Books, media, physical & digital resources